Table 1.

Adverse events, Proof of Mechanism study^a

Variableb	AZD7624	Placebo	Total
	(n=27)	(n=24)	(N=30)
Participants with any AE	6 (22.2)	9 (37.5)	13 (43.3)
Gastrointestinal disorders	1 (3.7)	0	1 (3.3)
Dry mouth	1 (3.7)	0	1 (3.3)
General disorders and administration site conditions	0	3 (12.5)	3 (10.0)
Influenza-like illness	0	1 (4.2)	1 (3.3)
Pyrexia	0	2 (8.3)	2 (6.7)
Infections and infestations	2 (7.4)	2 (8.3)	4 (13.3)
Folliculitis	0	1 (4.2)	1 (3.3)
Upper respiratory tract infection	2 (7.4)	1 (4.2)	3 (10.0)
Injury, poisoning, and procedural complications	0	1 (4.2)	1 (3.3)
Arthropod bite	0	1 (4.2)	1 (3.3)
Nervous system disorders	1 (3.7)	2 (8.3)	3 (10.0)
Dizziness	0	1 (4.2)	1 (3.3)
Headache	0	1 (4.2)	1 (3.3)
Presyncope	1 (3.7)	0	1 (3.3)

Notes: Data are shown as number (%) of participants.

^aThe safety analysis included patients who received a drug during the treatment period.

^bEvents were coded according to preferred terms in MedDRA, a standardized dictionary for clinical trials.³⁸

Abbreviation: AE, adverse event.